{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:01:22Z","timestamp":1785369682317,"version":"3.55.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH122446"],"award-info":[{"award-number":["R01MH122446"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH126940"],"award-info":[{"award-number":["R01MH126940"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["RF1MH120843"],"award-info":[{"award-number":["RF1MH120843"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32MH067631"],"award-info":[{"award-number":["T32MH067631"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Frontiers in Neuroendocrinology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.yfrne.2023.101098","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:17:10Z","timestamp":1692670630000},"page":"101098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-0921","authenticated-orcid":false,"given":"Jordan C.","family":"Barone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell P.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Wagner-Schuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tory A.","family":"Eisenlohr-Moul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5214\/ans.0972.7531.190403","article-title":"Effects of estrogen on the serotonergic system and calcitonin gene-related peptide in trigeminal ganglia of rats","volume":"19","author":"Aggarwal","year":"2012","journal-title":"Ann. Neurosci."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.fertnstert.2011.05.089","article-title":"Prevention of menstrual migraine with perimenstrual transdermal 17-\u03b2-estradiol: A randomized, placebo-controlled, double-blind crossover study","volume":"96","author":"Alm\u00e9n-Christensson","year":"2011","journal-title":"Fertil. Steril."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: Towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol."},{"key":"10.1016\/j.yfrne.2023.101098_b0020","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM\u20135) (5th ed.).","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0010-7824(92)90006-F","article-title":"Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations","volume":"46","author":"B\u00e4ckstr\u00f6m","year":"1992","journal-title":"Contraception"},{"key":"10.1016\/j.yfrne.2023.101098_b0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1196\/annals.1286.005","article-title":"Pathogenesis in menstrual cycle-linked CNS disorders","volume":"1007","author":"B\u00e4ckstr\u00f6m","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.yfrne.2023.101098_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2021.105426","article-title":"A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder","volume":"133","author":"B\u00e4ckstr\u00f6m","year":"2021","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02211800","article-title":"Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome","volume":"12","author":"Baker","year":"1995","journal-title":"J. Assist. Reprod. Genet."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/head.12457","article-title":"Statistical testing of association between menstruation and migraine","volume":"55","author":"Barra","year":"2015","journal-title":"Headache: J. Head Face Pain"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s10194-019-1035-7","article-title":"Identifying menstrual migraine\u2013 improving the diagnostic criteria using a statistical method","volume":"20","author":"Barra","year":"2019","journal-title":"J. Headache Pain"},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF00810354","article-title":"The effect of a synthetic GnRH analogue on catamenial epilepsy: A study in ten patients","volume":"239","author":"Bauer","year":"1992","journal-title":"J. Neurol."},{"key":"10.1016\/j.yfrne.2023.101098_b0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.psyneuen.2017.02.031","article-title":"Treatment of premenstrual dysphoric disorder with the GABA A receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial-NC-ND license (http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/)","volume":"80","author":"Bixo","year":"2017","journal-title":"Psychoneuroendocrinology"},{"issue":"5617","key":"10.1016\/j.yfrne.2023.101098_b0065","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/bmj.3.5617.531","article-title":"Double-blind Controlled Trial of a Micronized Preparation of Flumedroxone (Demigran) in Prophylaxis of Migraine","volume":"3","author":"Bradley","year":"1968","journal-title":"Br. Med. J."},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0070","first-page":"779","article-title":"Efficacy of depot leuprolide in premenstrual syndrome: Effect of symptom severity and type in a controlled trial","volume":"84","author":"Brown","year":"1994","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/head.13281","article-title":"The prevalence and impact of migraine and severe headache in the united states: figures and trends from government health studies","volume":"58","author":"Burch","year":"2018","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.yfrne.2023.101098_b0080","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.SMJ.0000129924.15619.D9","article-title":"A novel specific prophylaxis for menstrual-associated migraine","volume":"97","author":"Calhoun","year":"2004","journal-title":"South. Med. J."},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0085","first-page":"1001","article-title":"Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486","volume":"84","author":"Chan","year":"1994","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0090","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/jwh.2013.4485","article-title":"Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines","volume":"23","author":"Coffee","year":"2014","journal-title":"J. Women\u2019s Health"},{"key":"10.1016\/j.yfrne.2023.101098_b0095","doi-asserted-by":"crossref","unstructured":"Comasco, E., Kopp Kallner, H., Bixo, M., Hirschberg, A. L., Nyback, S., de Grauw, H., Epperson, C. N., & Sundstr\u00f6m-Poromaa, I., 2020. Ulipristal acetate for treatment of premenstrual dysphoric disorder: a proof-of-concept randomized controlled trial. Am. J. Psychiatry, appi.ajp.2020.20030286. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20030286.","DOI":"10.1176\/appi.ajp.2020.20030286"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0100","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1468-2982.2003.00516.x","article-title":"Menstrual migraine in a representative dutch population sample: prevalence, disability and treatment","volume":"23","author":"Couturier","year":"2003","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/03630242.2014.883658","article-title":"Does a disconnect occur between research and practice for premenstrual dysphoric disorder (PMDD) diagnostic procedures?","volume":"54","author":"Craner","year":"2014","journal-title":"Women Health"},{"key":"10.1016\/j.yfrne.2023.101098_b0110","doi-asserted-by":"crossref","unstructured":"Curtis, K.M., 2016a. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR. Recommendations and Reports, 65. https:\/\/doi.org\/10.15585\/mmwr.rr6503a1.","DOI":"10.15585\/mmwr.rr6503a1"},{"key":"10.1016\/j.yfrne.2023.101098_b0115","doi-asserted-by":"crossref","unstructured":"Curtis, K.M., 2016b. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR. Recommendations and Reports, 65. https:\/\/doi.org\/10.15585\/mmwr.rr6504a1.","DOI":"10.15585\/mmwr.rr6504a1"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0120","first-page":"585","article-title":"Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol","volume":"3","author":"De Berardis","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0125","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.fertnstert.2011.07.1089","article-title":"Combined oral contraceptives in women with menstrual migraine without aura","volume":"96","author":"De Leo","year":"2011","journal-title":"Fertil. Steril."},{"issue":"6561","key":"10.1016\/j.yfrne.2023.101098_b0130","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1136\/bmj.293.6561.1540","article-title":"Prevention of menstrual migraine by percutaneous oestradiol","volume":"293","author":"de Ligni\u00e8res","year":"1986","journal-title":"Br. Med. J. (Clin. Res. Ed)"},{"key":"10.1016\/j.yfrne.2023.101098_b0135","first-page":"5","volume":"290","author":"Dennerstein","year":"1985","journal-title":"Progesterone and the premenstrual syndrome: A double blind crossover trial."},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0165-0327(86)90070-4","article-title":"Treatment of premenstrual syndrome. A double-blind trial of dydrogesterone","volume":"11","author":"Dennerstein","year":"1986","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/09513598809023619","article-title":"Menstrual migraine: A double-blind trial of percutaneous estradiol","volume":"2","author":"Dennerstein","year":"1988","journal-title":"Gynecol. Endocrinol."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0150","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nature Reviews Disease Primers"},{"issue":"5\u20136","key":"10.1016\/j.yfrne.2023.101098_b0155","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0306-4530(90)90072-H","article-title":"Double-blind randomized crossover trial of luteal phase estrogens (premarin\u00ae) in the premenstrual syndrome (PMS)","volume":"15","author":"Dhar","year":"1990","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0160","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0015-0282(00)01707-6","article-title":"Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome","volume":"75","author":"Di Carlo","year":"2001","journal-title":"Fertil. Steril."},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0165","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1528-1157.1993.tb02097.x","article-title":"How common is catamenial epilepsy?","volume":"34","author":"Duncan","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yfrne.2023.101098_b0170","article-title":"Continuous or extended cycle vs. Cyclic use of combined hormonal contraceptives for contraception","volume":"7","author":"Edelman","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.yfrne.2023.101098_b0175","doi-asserted-by":"crossref","unstructured":"Eisenlohr-Moul, T. A., Barone, J. C., & Peters, J. (2022). P231. Effects of Acute Estradiol or Progesterone Administration on Perimenstrual Exacerbation of Suicidal Ideation, Depression, and Perceived Stress: Preliminary Analysis of a Three-Period Crossover Randomized Controlled Trial. Neuropsychopharmacology [ACNP 61st Annual Meeting: Poster Abstracts P1 - P270], 47(1), Article 1. https:\/\/doi.org\/10.1038\/s41386-022-01484-1.","DOI":"10.1038\/s41386-022-01484-1"},{"issue":"10","key":"10.1016\/j.yfrne.2023.101098_b0180","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/da.22673","article-title":"Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial","volume":"34","author":"Eisenlohr-Moul","year":"2017","journal-title":"Depress. Anxiety"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1176\/appi.ajp.2016.15121510","article-title":"Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS)","volume":"174","author":"Eisenlohr-Moul","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2023.101098_b0190","article-title":"Perimenstrual exacerbation of symptoms in borderline personality disorder: Evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System","volume":"1\u201311","author":"Eisenlohr-Moul","year":"2018","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0195","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41398-022-02294-1","article-title":"Effects of acute estradiol and progesterone on perimenstrual exacerbation of suicidal ideation and related symptoms: A crossover randomized controlled trial | Translational Psychiatry","volume":"12","author":"Eisenlohr-Moul","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0200","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.ajp.2012.11081302","article-title":"Premenstrual dysphoric disorder: evidence for a new category for DSM-5","volume":"169","author":"Epperson","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2023.101098_b0205","article-title":"Migraine","volume":"8(1), Article 1","author":"Ferrari","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"Suppl 1","key":"10.1016\/j.yfrne.2023.101098_b0210","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/s10072-011-0532-5","article-title":"Female reproductive steroids and neuronal excitability","volume":"32","author":"Finocchi","year":"2011","journal-title":"Neurol. Sci.: Official J. Italian Neurol. Soc. Italian Soc. Clin. Neurophysiol."},{"issue":"6 suppl 2","key":"10.1016\/j.yfrne.2023.101098_b0215","first-page":"S2","article-title":"Catamenial epilepsy: Pathophysiology, diagnosis, and management","volume":"61","author":"Foldvary-Schaefer","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0220","first-page":"CD003415","article-title":"Progesterone for premenstrual syndrome","volume":"2012","author":"Ford","year":"2012","journal-title":"The Cochrane Database Syst. Rev."},{"key":"10.1016\/j.yfrne.2023.101098_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7812\/TPP\/19.145","article-title":"A clinical approach to catamenial epilepsy: a review","volume":"24","author":"Frank","year":"2020","journal-title":"Perm. J."},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jama.1990.03450030073035","article-title":"Ineffectiveness of progesterone suppository treatment for premenstrual syndrome","volume":"264","author":"Freeman","year":"1990","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0235","first-page":"192","article-title":"Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: A pilot study","volume":"54","author":"Freeman","year":"1993","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1995.03530010065036","article-title":"A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome","volume":"274","author":"Freeman","year":"1995","journal-title":"J. Am. Med. Assoc."},{"issue":"9","key":"10.1016\/j.yfrne.2023.101098_b0245","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1176\/ajp.156.9.1403","article-title":"Characteristics of placebo responses in medical treatment of premenstrual syndrome","volume":"156","author":"Freeman","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0250","first-page":"303","article-title":"Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: A controlled study","volume":"33","author":"Freeman","year":"1997","journal-title":"Psychopharmacol. Bull."},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0255","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/15246090152543148","article-title":"Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder","volume":"10","author":"Freeman","year":"2001","journal-title":"J. Women\u2019s Health & Gender-Based Medicine"},{"key":"10.1016\/j.yfrne.2023.101098_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2011.09.010","article-title":"An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg\/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual \\ldots","author":"Freeman","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.yfrne.2023.101098_b0265","unstructured":"Freeman, E.W., 2002. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur. J. Contraception & Reprod. Health Care\u00a0: Official J. Eur. Soc. Contraception, 7 Suppl 3, 27\u201334; discussion 42-43."},{"issue":"7","key":"10.1016\/j.yfrne.2023.101098_b0270","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jnr.24632","article-title":"Pharmacological sex hormone manipulation as a risk model for depression","volume":"98","author":"Frokjaer","year":"2020","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0275","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/01674829709085567","article-title":"A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder","volume":"18","author":"Gehlert","year":"2009","journal-title":"J. Psychosom. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S003329170800322X","article-title":"The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women","volume":"39","author":"Gehlert","year":"2009","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0285","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-3999(92)90090-O","article-title":"A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive","volume":"36","author":"Graham","year":"1992","journal-title":"J. Psychosom. Res."},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10194-007-0417-4","article-title":"Frovatriptan vs. Transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine","volume":"8","author":"Guidotti","year":"2007","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0295","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yebeh.2008.02.004","article-title":"The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: Implications for diagnosis and treatment","volume":"13","author":"Guille","year":"2008","journal-title":"Epilepsy & Behavior : E&B"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.contraception.2011.05.008","article-title":"Continuous oral levonorgestrel\/ethinyl estradiol for treating premenstrual dysphoric disorder","volume":"85","author":"Halbreich","year":"2012","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/00016348809004191","article-title":"Induced Anovulation As Treatment Of Premenstrual Tension Syndrome: A double-blind cross-over study with GnRH-agonist versus placebo","volume":"67","author":"Hammarb\u00e4ck","year":"2009","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0310","first-page":"132","article-title":"Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome","volume":"125","author":"Hammarb\u00e4ck","year":"1991","journal-title":"Acta Endocrinol."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0315","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/clipsy.8.2.242","article-title":"Differentiating premenstrual dysphoric disorder from premenstrual exacerbations of other disorders: a methods dilemma","volume":"8","author":"Hartlage","year":"2001","journal-title":"Clin. Psychol. Sci. Pract."},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0320","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/01.psy.0000138131.92408.b9","article-title":"Premenstrual exacerbation of depressive disorders in a community-based sample in the United States","volume":"66","author":"Hartlage","year":"2004","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.yfrne.2023.101098_b0325","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. (2018). Cephalalgia, 38(1), 1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0330","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0020-7292(91)90357-B","article-title":"Premenstrual tension: A placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate","volume":"34","author":"Hellberg","year":"1991","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"9","key":"10.1016\/j.yfrne.2023.101098_b0335","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.45.9.1660","article-title":"Progesterone therapy in women with complex partial and secondary generalized seizures","volume":"45","author":"Herzog","year":"1995","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.seizure.2007.11.014","article-title":"Catamenial epilepsy: Definition, prevalence pathophysiology and treatment","volume":"17","author":"Herzog","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yfrne.2023.101098_b0345","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.seizure.2015.02.024","article-title":"Catamenial epilepsy: Update on prevalence, pathophysiology and treatment from the findings of the NIH Progesterone Treatment Trial","volume":"28","author":"Herzog","year":"2015","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0350","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1111\/epi.17261","article-title":"Association between family history of alcohol use disorder and catamenial epilepsy","volume":"63","author":"Herzog","year":"2022","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0355","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ana.10508","article-title":"Seizure exacerbation associated with inhibition of progesterone metabolism","volume":"53","author":"Herzog","year":"2003","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0360","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1212\/WNL.0000000000000623","article-title":"Allopregnanolone levels and seizure frequency in progesterone-treated women with epilepsy","volume":"83","author":"Herzog","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.yfrne.2023.101098_b0365","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1528-1157.1997.tb01197.x","article-title":"Three patterns of catamenial epilepsy","volume":"38","author":"Herzog","year":"1997","journal-title":"Epilepsia"},{"issue":"24","key":"10.1016\/j.yfrne.2023.101098_b0370","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1212\/WNL.0b013e318259e1f9","article-title":"Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial","volume":"78","author":"Herzog","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yfrne.2023.101098_b0375","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.yebeh.2016.04.020","article-title":"Differential impact of contraceptive methods on seizures varies by antiepileptic drug category: Findings of the Epilepsy Birth Control Registry","volume":"60","author":"Herzog","year":"2016","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0380","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/epi.13320","article-title":"Contraceptive practices of women with epilepsy: Findings of the epilepsy birth control registry","volume":"57","author":"Herzog","year":"2016","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0385","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/02813438809009313","article-title":"The effect of dydrogesterone on premenstrual symptoms. A double-blind, randomized, placebo-controlled study in general practice","volume":"6","author":"Hoffmann","year":"1988","journal-title":"Scand. J. Prim. Health Care"},{"key":"10.1016\/j.yfrne.2023.101098_b0390","doi-asserted-by":"crossref","unstructured":"Hussain, S.Y., Massil, J.H., Matta, W.H., Shaw, R.W., O\u2019brien, P.M.S., 1992. Buserelin in premenstrual syndrome. Gynecological Endocrinology, 6(1), 57\u201364. https:\/\/doi.org\/10.3109\/09513599209081007.","DOI":"10.3109\/09513599209081007"},{"issue":"7","key":"10.1016\/j.yfrne.2023.101098_b9015","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"American Journal of psychiatry"},{"issue":"12","key":"10.1016\/j.yfrne.2023.101098_b0395","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.4088\/JCP.v68n1218","article-title":"Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: A preliminary report","volume":"68","author":"Joffe","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.yfrne.2023.101098_b0400","first-page":"24","article-title":"Catamenial epilepsy: A missed cause of refractory seizure in young women","volume":"11","author":"Kandeepan","year":"2016","journal-title":"Malaysian Family Phys.: Official J. Acad. Family Phys. Malaysia"},{"key":"10.1016\/j.yfrne.2023.101098_b0405","unstructured":"Kaunitz, A., 2022. Hormonal contraception for suppression of menstruation. In: UpToDate. Post TW, Ed."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0410","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0165-0327(93)90026-G","article-title":"Sex and depression in the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence","volume":"29","author":"Kessler","year":"1993","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0415","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0420","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijgo.2009.01.016","article-title":"Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome","volume":"105","author":"Khajehei","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0425","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/GRF.0b013e318159c06a","article-title":"Combined oral contraceptives: a comprehensive review","volume":"50","author":"Kiley","year":"2007","journal-title":"Clin. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0430","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3988\/jcn.2020.16.4.723","article-title":"Successful experience of cyclic progesterone supplementation in catamenial epilepsy","volume":"16","author":"Kim","year":"2020","journal-title":"J. Clin. Neurol. (Seoul, Korea)"},{"issue":"11","key":"10.1016\/j.yfrne.2023.101098_b0435","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11920-021-01286-0","article-title":"Premenstrual exacerbations of mood disorders: findings and knowledge gaps","volume":"23","author":"Kuehner","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.yfrne.2023.101098_b0440","article-title":"Types of progestogens in combined oral contraception: Effectiveness and side-effects","volume":"5","author":"Lawrie","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0445","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/09513599909167531","article-title":"The treatment of severe premenstrual syndrome with goserelin with and without \u2018add-back\u2019 estrogen therapy: A placebo-controlled study","volume":"13","author":"Leather","year":"1999","journal-title":"Gynecol. Endocrinol."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0450","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s42494-021-00057-x","article-title":"Psychogenic non-epileptic seizures (PNES) in the context of concurrent epilepsy \u2013 making the right diagnosis","volume":"3","author":"Liampas","year":"2021","journal-title":"Acta Epileptologica"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0455","first-page":"313","article-title":"The use of leuprolide acetate in the diagnosis and treatment of menstrual migraine-the role of artificially-induced menopause","volume":"6","author":"Lichten","year":"1995","journal-title":"Headache Quarterly-Curr. Treatment Res."},{"key":"10.1016\/j.yfrne.2023.101098_b0460","first-page":"CD006586","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","volume":"2","author":"Lopez","year":"2012","journal-title":"The Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.yfrne.2023.101098_b0465","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1212\/01.wnl.0000249114.52802.55","article-title":"Prevention of menstrual attacks of migraine: A double blind placebo controlled crossover study","volume":"67","author":"MacGregor","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0470","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1783\/147118907779399684","article-title":"Menstrual migraine: A clinical review","volume":"33","author":"MacGregor","year":"2007","journal-title":"Journal of Family Planning and Reproductive Health Care"},{"key":"10.1016\/j.yfrne.2023.101098_b0475","doi-asserted-by":"crossref","unstructured":"MacGregor, E.A., Guillebaud, J., 2018. The 7-day contraceptive hormone-free interval should be consigned to history. BMJ Sexual & Reproductive Health, bmjsrh-2017-200036. https:\/\/doi.org\/10.1136\/bmjsrh-2017-200036.","DOI":"10.1136\/bmjsrh-2017-200036"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0480","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0002-9378(86)90604-6","article-title":"A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome","volume":"154","author":"Maddocks","year":"1986","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"400","key":"10.1016\/j.yfrne.2023.101098_b0485","first-page":"589","article-title":"Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Progesterone Study Group","volume":"45","author":"Magill","year":"1995","journal-title":"The Br. J. General Practice : J. Royal College of General Practitioners"},{"issue":"11","key":"10.1016\/j.yfrne.2023.101098_b0490","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.46.11.1044","article-title":"Treatment of menstrual migraine by oestradiol implants","volume":"46","author":"Magos","year":"1983","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6536","key":"10.1016\/j.yfrne.2023.101098_b0495","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/bmj.292.6536.1629","article-title":"Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: Placebo controlled study","volume":"292","author":"Magos","year":"1986","journal-title":"Br. Med. J. (Clin. Res. Ed)"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0500","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1526-4610.2010.01627.x","article-title":"A prospective comparison between ICHD-II and probability menstrual migraine diagnostic criteria","volume":"50","author":"Marcus","year":"2010","journal-title":"Headache: J. Head Face Pain"},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0505","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2010.10.029","article-title":"Ethinyl estradiol 20\u03bcg\/drospirenone 3mg 24\/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder","volume":"113","author":"Marr","year":"2011","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0510","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.contraception.2010.10.010","article-title":"Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24\/4 regimen","volume":"84","author":"Marr","year":"2011","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0515","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1526-4610.2003.03065.x","article-title":"Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache","volume":"43","author":"Martin","year":"2003","journal-title":"Headache: J. Head Face Pain"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0520","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1526-4610.2006.00306.x","article-title":"Symptoms of premenstrual syndrome and their association with migraine headache","volume":"46","author":"Martin","year":"2006","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0525","doi-asserted-by":"crossref","first-page":"Article 4","DOI":"10.1038\/npp.2015.246","article-title":"5\u03b1 -reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder","volume":"41","author":"Martinez","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.yfrne.2023.101098_b0530","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1212\/WNL.34.9.1255","article-title":"Treatment of seizures with medroxyprogesterone acetate: Preliminary report","volume":"34","author":"Mattson","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.yfrne.2023.101098_b0535","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1210\/rp.57.1.357","article-title":"Estrogen actions throughout the brain","volume":"57","author":"McEwen","year":"2002","journal-title":"Recent Prog. Horm. Res."},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0540","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0015-0282(16)57053-8","article-title":"Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome","volume":"62","author":"Mezrow","year":"1994","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0545","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0031-9384(99)00094-3","article-title":"The role of low progesterone and tension as triggers of perimenstrual chocolate and sweets craving: Some negative experimental evidence","volume":"67","author":"Michener","year":"1999","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0550","doi-asserted-by":"crossref","first-page":"252A","DOI":"10.1210\/jcem-72-2-252","article-title":"Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen\/progestin","volume":"72","author":"Mortola","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0555","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med. Res. Method."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0560","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0015-0282(97)81928-0","article-title":"Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and \u201cadd-back\u201d therapy","volume":"67","author":"Murray","year":"1997","journal-title":"Fertil. Steril."},{"issue":"21","key":"10.1016\/j.yfrne.2023.101098_b0565","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM198411223112104","article-title":"The premenstrual syndrome. Effects of \u201cmedical ovariectomy\u201d","volume":"311","author":"Muse","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yfrne.2023.101098_b0570","first-page":"CD010503","article-title":"Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome","volume":"3","author":"Naheed","year":"2017","journal-title":"The Cochrane Database Syst. Rev."},{"key":"10.1016\/j.yfrne.2023.101098_b0575","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/2277-9175.107974","article-title":"Progesterone therapy in women with intractable catamenial epilepsy","volume":"2","author":"Najafi","year":"2013","journal-title":"Advanced Biomedical Research"},{"key":"10.1016\/j.yfrne.2023.101098_b0580","doi-asserted-by":"crossref","unstructured":"Nappi, R. E., Sances, G., Brundu, B., De taddei, S., Sommacal, A., Ghiotto, N., Polatti, F., & Nappi, G. (2005). Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Human Reproduction, 20(12), 3423\u20133428. https:\/\/doi.org\/10.1093\/humrep\/dei260.","DOI":"10.1093\/humrep\/dei260"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0585","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1528-1157.1980.tb04074.x","article-title":"Catamenial Epilepsy: A Review","volume":"21","author":"Newmark","year":"1980","journal-title":"Epilepsia"},{"key":"10.1016\/j.yfrne.2023.101098_b0590","doi-asserted-by":"crossref","DOI":"10.1007\/s00737-022-01246-4","article-title":"Premenstrual exacerbation of mental health disorders: A systematic review of prospective studies","author":"Nolan","year":"2022","journal-title":"Archives of Women\u2019s Mental Health"},{"key":"10.1016\/j.yfrne.2023.101098_b0595","article-title":"Asarina Pharma reports topline results in Phase IIa Menstrual Migraine study","author":"Nordkild","year":"2021","journal-title":"News Powered by Cision."},{"key":"10.1016\/j.yfrne.2023.101098_b0600","unstructured":"O\u2019Neal, M. (2022). Estrogen-Associated Migraine. In UpToDate. Post TW, Ed."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0605","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s10194-015-0503-y","article-title":"Burden of migraine related to menses: Results from the AMPP study","volume":"16","author":"Pavlovi\u0107","year":"2015","journal-title":"J. Headache Pain"},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0610","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","article-title":"Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation","volume":"72","author":"Pearlstein","year":"2005","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.yfrne.2023.101098_b0615","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/JCP.0000000000000761","article-title":"Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo","volume":"37","author":"Peters","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0620","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jrsm.1123","article-title":"A scoping review of scoping reviews: Advancing the approach and enhancing the consistency","volume":"5","author":"Pham","year":"2014","journal-title":"Res. Synth. Methods"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0625","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jpsychires.2010.07.006","article-title":"Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics","volume":"45","author":"Pincus","year":"2011","journal-title":"J. Psychiatr. Res."},{"issue":"10","key":"10.1016\/j.yfrne.2023.101098_b0630","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0333102409359315","article-title":"Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine","volume":"30","author":"Pinkerman","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.yfrne.2023.101098_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2023.101060","article-title":"Progesterone and contraceptive progestin actions on the brain: A systematic review of animal studies and comparison to human neuroimaging studies","volume":"69","author":"Pletzer","year":"2023","journal-title":"Front. Neuroendocrinol."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0640","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tics.2011.12.011","article-title":"Neural circuits underlying the pathophysiology of mood disorders","volume":"16","author":"Price","year":"2012","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.yfrne.2023.101098_b0645","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-023-11706-1","article-title":"Migraine: From pathophysiology to treatment","author":"Puledda","year":"2023","journal-title":"J. Neurol."},{"issue":"2\u20133","key":"10.1016\/j.yfrne.2023.101098_b0650","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.eplepsyres.2004.09.003","article-title":"Role of neurosteroids in catamenial epilepsy","volume":"62","author":"Reddy","year":"2004","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2009.02.017","article-title":"The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy","volume":"85","author":"Reddy","year":"2009","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0660","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/14737175.2016.1243472","article-title":"Do oral contraceptives increase epileptic seizures?","volume":"17","author":"Reddy","year":"2017","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0665","doi-asserted-by":"crossref","first-page":"e13028","DOI":"10.1111\/jne.13028","article-title":"Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women","volume":"34","author":"Reddy","year":"2022","journal-title":"J. Neuroendocrinol."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0670","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/wps.20611","article-title":"Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders","volume":"18","author":"Reed","year":"2019","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0675","doi-asserted-by":"crossref","first-page":"187","DOI":"10.31887\/DCNS.2018.20.3\/drubinow","article-title":"Is there a role for reproductive steroids in the etiology and treatment of affective disorders?","volume":"20","author":"Rubinow","year":"2018","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.yfrne.2023.101098_b0680","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1192\/bjp.135.3.209","article-title":"Premenstrual syndrome: A double-blind controlled trial of progesterone and placebo","volume":"135","author":"Sampson","year":"1979","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.yfrne.2023.101098_b0685","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1192\/bjp.153.2.232","article-title":"Premenstrual syndrome. A double-blind cross-over study of treatment with dydrogesterone and placebo","volume":"153","author":"Sampson","year":"1988","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0690","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0695","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/j.2040-4603.2016.tb00705.x","article-title":"Reproductive Steroid Regulation of Mood and Behavior","volume":"6","author":"Schiller","year":"2016","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.yfrne.2023.101098_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2020.104895","article-title":"How to study the menstrual cycle: Practical tools and recommendations","volume":"123","author":"Schmalenberger","year":"2021","journal-title":"Psychoneuroendocrinology"},{"issue":"17","key":"10.1016\/j.yfrne.2023.101098_b0705","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM199104253241705","article-title":"Lack of effect of induced menses on symptoms in women with premenstrual syndrome","volume":"324","author":"Schmidt","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0710","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199801223380401","article-title":"Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome","volume":"338","author":"Schmidt","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.yfrne.2023.101098_b0715","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2017.16101113","article-title":"Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels","volume":"174","author":"Schmidt","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0720","doi-asserted-by":"crossref","first-page":"139.e1","DOI":"10.1016\/j.ajog.2009.03.016","article-title":"Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder","volume":"201","author":"Segebladh","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.yfrne.2023.101098_b0725","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","article-title":"Premature menopause or early menopause: Long-term health consequences","volume":"65","author":"Shuster","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.yfrne.2023.101098_b0730","doi-asserted-by":"crossref","unstructured":"Smite, M. g., van der Meer, Y. g., Pfeil, J. p. j. m., Rijnierse, J. j. m. m., & Vos, A. j. m. (1994). Perimenstrual Migraine: Effect of Estraderm TTS(r) and the Value of Contingent Negative Variation and Exteroceptive Temporalis Muscle Suppression Test. Headache: The Journal of Head and Face Pain, 34(2), 103\u2013106. https:\/\/doi.org\/10.1111\/j.1526-4610.1994.hed3402103.x.","DOI":"10.1111\/j.1526-4610.1994.hed3402103.x"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0735","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2007.03.008","article-title":"Neurosteroid regulation of GABAA receptors: Focus on the \u03b14 and \u03b4 subunits","volume":"116","author":"Smith","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0740","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1471-0528.1995.tb11321.x","article-title":"A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome","volume":"102","author":"Smith","year":"1995","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"8","key":"10.1016\/j.yfrne.2023.101098_b0745","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/WNL.21.8.853","article-title":"The role of progesterone in menstrual migraine","volume":"21","author":"Somerville","year":"1971","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0750","first-page":"93","article-title":"The Influence of Progesterone and Estradiol Upon Migraine. Headache: The Journal of Head and Face","volume":"12","author":"Somerville","year":"1972","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0755","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1212\/WNL.22.4.355","article-title":"The role of estradiol withdrawal in the etiology of menstrual migraine","volume":"22","author":"Somerville","year":"1972","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0760","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/WNL.25.3.239","article-title":"Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration","volume":"25","author":"Somerville","year":"1975","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0765","article-title":"Headaches and Oral Contraceptives: Impact of Eliminating the Standard 7-Day Placebo Interval. Headache: The Journal of Head and Face","volume":"47","author":"Sulak","year":"2007","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.yfrne.2023.101098_b0770","first-page":"891","article-title":"Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen","volume":"78","author":"Sundstr\u00f6m","year":"1999","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"9","key":"10.1016\/j.yfrne.2023.101098_b0775","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/humrep\/13.9.2402","article-title":"Placebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral beta-endorphin concentrations in premenstrual syndrome","volume":"13","author":"Taskin","year":"1998","journal-title":"Hum. Reprod."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0780","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/bdi.12138","article-title":"Effects of the menstrual cycle on bipolar disorder","volume":"16","author":"Teatero","year":"2014","journal-title":"Bipolar Disord."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0785","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12874-016-0116-4","article-title":"A scoping review on the conduct and reporting of scoping reviews","volume":"16","author":"Tricco","year":"2016","journal-title":"BMC Med. Res. Method."},{"issue":"1","key":"10.1016\/j.yfrne.2023.101098_b0790","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/01674829609025661","article-title":"Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration","volume":"17","author":"Vanselow","year":"1996","journal-title":"J. Psychosom. Obstet. Gynaecol."},{"issue":"11\u201312","key":"10.1016\/j.yfrne.2023.101098_b0795","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1177\/03331024221099031","article-title":"Validation of diagnostic ICHD-3 criteria for menstrual migraine","volume":"42","author":"Verhagen","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.yfrne.2023.101098_b0800","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2147\/IJWH.S28872","article-title":"Diagnosis and management of catamenial seizures: A review","volume":"4","author":"Verrotti","year":"2012","journal-title":"Int. J. Women\u2019s Health"},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0805","doi-asserted-by":"crossref","first-page":"47578","DOI":"10.4088\/JCP.22r14614","article-title":"What\u2019s Stopping Us? Using GnRH Analogs With Stable Hormone Addback in Treatment-Resistant Premenstrual Dysphoric Disorder: Practical Guidelines and Risk-Benefit Analysis for Long-term Therapy","volume":"84","author":"Wagner-Schuman","year":"2023","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"8665","key":"10.1016\/j.yfrne.2023.101098_b0810","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0140-6736(89)90784-8","article-title":"TREATMENT OF SEVERE PREMENSTRUAL SYNDROME WITH OESTRADIOL PATCHES AND CYCLICAL ORAL NORETHISTERONE","volume":"334","author":"Watson","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.yfrne.2023.101098_b0815","series-title":"UpToDate","author":"Welt","year":"2022"},{"issue":"1\u20132","key":"10.1016\/j.yfrne.2023.101098_b0820","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0028-2243(90)90015-S","article-title":"Inhibition of ovulation with oral progestins\u2014Effectiveness in premenstrual syndrome","volume":"34","author":"West","year":"1990","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0825","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/oxfordjournals.humrep.a138633","article-title":"Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome","volume":"9","author":"West","year":"1994","journal-title":"Hum. Reprod."},{"issue":"4","key":"10.1016\/j.yfrne.2023.101098_b0830","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/GCO.0000000000000082","article-title":"Selective progesterone receptor modulators","volume":"26","author":"Whitaker","year":"2014","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"10, Part 1","key":"10.1016\/j.yfrne.2023.101098_b0835","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/j.neubiorev.2012.12.007","article-title":"The neurobiology of depression and antidepressant action","volume":"37","author":"Willner","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.yfrne.2023.101098_b0840","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1517\/13543784.16.11.1851","article-title":"Leuprolide acetate: A drug of diverse clinical applications","volume":"16","author":"Wilson","year":"2007","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.yfrne.2023.101098_b0845","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1471-0528.2004.00135.x","article-title":"The effectiveness of GnRHa with and without \u201cadd-back\u201d therapy in treating premenstrual syndrome: A meta analysis","volume":"111","author":"Wyatt","year":"2004","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.yfrne.2023.101098_b0850","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstet. Gynecol."},{"issue":"31","key":"10.1016\/j.yfrne.2023.101098_b0855","doi-asserted-by":"crossref","first-page":"821","DOI":"10.15585\/mmwr.mm6631a1","article-title":"National and State Estimates of the Numbers of Adults and Children with Active Epilepsy\u2014United States, 2015","volume":"66","author":"Zack","year":"2017","journal-title":"Morb. Mortal. Wkly Rep."}],"container-title":["Frontiers in Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302223000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302223000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:25:24Z","timestamp":1758774324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091302223000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":172,"alternative-id":["S0091302223000468"],"URL":"https:\/\/doi.org\/10.1016\/j.yfrne.2023.101098","relation":{},"ISSN":["0091-3022"],"issn-type":[{"value":"0091-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy","name":"articletitle","label":"Article Title"},{"value":"Frontiers in Neuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yfrne.2023.101098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101098"}}